Aeglea BioTherapeutics, Inc.
AGLE
AGLE: Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. The company competes in the segments of the pharmaceutical, biotechnology and other related markets that address rare genetic diseases.
moreShow AGLE Financials
Recent trades of AGLE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AGLE's directors and management
Government lobbying spending instances
-
$30,000 Apr 20, 2023 Issue: None
-
$30,000 Jan 19, 2023 Issue: None
-
$30,000 Oct 18, 2022 Issue: None
-
$20,000 Jul 20, 2022 Issue: Pharmacy
-
$20,000 Apr 20, 2022 Issue: None
-
$30,000 Jan 20, 2022 Issue: None
-
$30,000 Oct 20, 2021 Issue: Health Issues
-
$30,000 Jul 20, 2021 Issue: Health Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues Pharmacy
-
$30,000 Jan 21, 2021 Issue: None
-
$10,000 Oct 20, 2020 Issue: Health Issues Pharmacy
-
$40,000 Aug 03, 2020 Issue: Pharmacy
New patents grants
Federal grants, loans, and purchases
Followers on AGLE's company Twitter account
Number of mentions of AGLE in WallStreetBets Daily Discussion
Recent insights relating to AGLE
Recent picks made for AGLE stock on CNBC
ETFs with the largest estimated holdings in AGLE
Flights by private jets registered to AGLE